77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 57

77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis

77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis

Background/Significance

The identification of the tumor bed following lumpectomy is vital for successful radiation treatment, both for a breast radiation boost and more fundamentally in the partial breast setting. However, identification of the tumor cavity on a planning CT scan can be complicated as postsurgical seromas will inversely decrease with time and preoperative imaging may not anatomically correlate. In addition, the radiation target should correlate with the tumor pathology size. VeraForm is a radio-opaque continuous multiplane marker that is sutured into the operative bed during the lumpectomy. The aim of this study is to compare VeraForm markers (VF), surgical clip (SC) placement, and no clips (NC) on target delineation in relation to the tumor bed.

Materials and Methods

Beginning in July 2023, a single breast surgeon placed VF in lumpectomy. We retrospectively reviewed 48 women, 19 women with VF and compared with 13 women with SC and 24 women with NC. The tumor volume was calculated by taking the surgical specimen 3-dimensional measurements and multiplying it by π/6. We created a ratio between the specimen and the CTV (radiation target volume of the tumor bed, which was created by a board certified radiation oncologist). We then used a 2 sample Welch t-test to compare 3 populations.

Results

The population was mainly T0 (28%) and T1 (58%). The treatment was whole breast with a cavity boost in 57% and partial breast in 43%. The medium weight of the patients between VF, SC, and NC was similar (169 lbs, 174 lbs, 169 lbs, respectively), and the time from surgery to radiation mapping was similar (33 days, 40 days, 42 days, respectively). The tumor volume for VF, SC, and NC was 40 mL, 47 mL, and 54 mL, respectively (P = not specified). However, the VF ratio to tumor volume had less variance than NC (P = .0436) but showed no improvement over the SC (P = .289). SC did not show an improvement over NC (P = .239).

Conclusion

In this single-institution retrospective study, VF led to a target volume that was more consistent with the tumor specimen size than no markers. However, it did not yield an improvement over SC placement.

Articles in this issue

77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
77 A Radio Opaque Suture May Improve Radiation Target Delineation in Post Lumpectomy Patients With Breast Cancer: A Retrospective Analysis
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
78 Comparison of Positive Margin Rate of Breast Cancer in Higher BMI Patients
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
79 Case Series of Pathologic Upgrade After Reconstructive Breast Surgery
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
81 Assessing Recurrence Likelihood in Hormone Receptor–Positive/HER2-Negative Breast Cancer Patients Directly From MRI Using Imaging AI
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
82 Efficacy, Safety, and Biomarker Analysis of ICARUS-BREAST01: A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients With HR+/HER2– Advanced Breast Cancer
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
84 EQUALS: Vaginal/Sexual Health in Patients With Estrogen Receptor–Positive/HER2- Metastatic Breast Cancer
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
86 Elacestrant Combinations in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer: Update From ELEVATE, a Phase 1b/2, Open-Label, Umbrella Study
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
87 Elacestrant Plus Abemaciclib Combination in Patients With Estrogen Receptor-positive, HER2-Negative Advanced or Metastatic Breast Cancer
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
88 Eflapegrastim, a Long-Acting Granulocyte Colony–Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer
96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States
96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Related Content